Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Current Leases for 5 consecutive years, with $583000.0 as the latest value for Q3 2025.

  • Quarterly Current Leases rose 471.57% to $583000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $583000.0 through Sep 2025, up 471.57% year-over-year, with the annual reading at $42000.0 for FY2024, 82.28% down from the prior year.
  • Current Leases hit $583000.0 in Q3 2025 for ARS Pharmaceuticals, down from $589000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.1 million in Q1 2022 to a low of $42000.0 in Q4 2024.
  • Historically, Current Leases has averaged $435315.8 across 5 years, with a median of $233000.0 in 2023.
  • Biggest five-year swings in Current Leases: crashed 82.28% in 2024 and later soared 471.57% in 2025.
  • Year by year, Current Leases stood at $144000.0 in 2021, then soared by 59.72% to $230000.0 in 2022, then rose by 3.04% to $237000.0 in 2023, then plummeted by 82.28% to $42000.0 in 2024, then surged by 1288.1% to $583000.0 in 2025.
  • Business Quant data shows Current Leases for SPRY at $583000.0 in Q3 2025, $589000.0 in Q2 2025, and $73000.0 in Q1 2025.